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Abstract
Background: Renal denervation (RDN) is as an effective treatment for heart failure (HF), but its ef-
fects on cardiac function of patients with HF are not well documented. Here, the aim was to investigate 
RDN’s effect on patients with chronic systolic HF, by conducting a single-center, prospective, rand-
omized, and controlled study.
Methods: Sixty patients with chronic systolic HF were randomly assigned to the RDN or control 
groups, receiving percutaneous catheter-based RDN with radiofrequency ablation and drug treatment, 
respectively. All patients performed a 6-minute walk test, echocardiography, blood pressure measure-
ment, and biochemical test, at both baseline and in a 6-month follow up.
Results: Over 6-month follow up, patients in RDN group showed a decrease in N-terminal pro-B-type 
natriuretic peptide (440.1 ± 226.5 pg/mL vs. 790.8 ± 287.0 pg/mL, p < 0.001, Cohen’s d = 1.14), an 
increase in left ventricular ejection fraction (39.1 ± 7.3% vs. 35.6 ± 3.3%, p = 0.017, Cohen’s d = 0.61), 
improved New York Heart Association class assessment (p = 0.01, Cohen’s d = 0.66), and decreased 
blood pressures (p < 0.001, Cohen’s d = 0.91), without reporting hypotension and syncope amaurosis. No 
significant between-group difference was observed for glomerular filtration rate and heart rate.
Conclusions: Renal denervation which effectively and safely improves patient’s cardiac function as 
well as exercise tolerance, could be considered as an effective treatment for chronic systolic HF. (Cardiol J  
2019; 26, 5: 503–510)
Key words: renal denervation, sympathetic nervous system, heart failure,  
blood pressure, cardiology
Introduction
Chronic heart failure (HF) is a common disease 
suffered by around 100 million people all over the 
world. There were 5.1 million people in United 
States at present a number which increases at 
a rate of 800,000 cases per year whosuffer from 
this disease. HF is believed to be a major cause of 
sudden cardiac death, and previous studies have 
shown that the death rate for patients with chronic 
HF is 6–9 times higher than those in the normal 
population. Around 300,000 deaths are caused by 
HF every year in United States [1]. The medical 
expense on HF reachedas much as $30 billion in 
2012,and has kept growing in recent years [2]. 
Excessive activity of the sympatheic nerve 
system is believed as one of the major causes of the 
HF progression. Sympathetic activation involves 
efferent and afferent pathways to regulate cardio-
vascular functions such as blood pressure (BP) and 
heart rate, in response to acute stress like volume 
depletion or excessive vasodilatation [3]. Exces-
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sive activity of the sympathetic nervous system 
has a direct adverse consequence for cardiovascular 
diseases, particularly for HF and hypertension [4]. 
A proper suppression of the sympathetic nervous 
system activity may be able to improve the condi-
tions of patients with HF. Particularly, catheter-
based renal sympathetic denervation (RDN), which 
can specificly and effectively reduce the activity 
of sympatheic nervous system [3, 5], which is 
considered a proper treatment for HF. 
Renal denervation was implemented by se-
lective sympathetic denervation of the human 
kidney with radiofrequency energy ablation. It was 
firstly proposed to treat resistant hypertension 
[6, 7], but its treatment effect for this specific dis-
ease was not as good as had been imagined. HTN-3 
study found that there was no significant difference 
in BP between the RDN and sham groups [8]. 
Even though, its ability in suppressing the activity 
of the sympathetic nervous system suggests it is 
a possible application in the treatment of HF. 
To explore the treatment effect of RDN on 
HF, several animal models, e.g.pig and rat models, 
were established [9–11] and the performance of 
RDN on these animal models were quite promis-
sing. However, these animal based results were 
insufficient to be considered as direct evidence for 
the application of RDN in clinical practice; more 
experiments on humans should be conducted to 
eliminate the concerns regarding its effectiveness 
and safety to patients with HF. A first-in-man study 
of chronic systolic HF has already been conducted 
[12], and suggests that patient exercise tolerances 
were improved after the intervention of RDN. Ne-
vertheless, small sample size and its single-group 
non-blinded and non-randomized nature limited 
the validity of these research findings. Thus, the 
aim presently was to comprehensively investiga-
te the effectiveness and safety of catheter-based 
RDN in the treatment of chronic systolic HF, by 
conducting a randomized controlled trial with 
a larger sample size. 
Methods
Patients
Sixty patients with chronic systolic HF (New 
York Heart Association [NYHA] class II or III) 
were recruited in this study. All patients were not 
less than 18 years old. The inclusion criteria were: 
(1) left ventricular ejection fraction (LVEF) should be 
smaller than 40% at echocardiography or N-termi-
nal pro-B-type natriuretic peptide (NT-proBNP) 
should be larger than 125 pg/mL; (2) glomerular 
filtration rate (GFR) should not be smaller than 
45 mL/min/1.73 m2 and systolic BP should not be 
smaller than 100 mmHg. The exclusion criteria 
were: (1) patients with renal artery stenosis (in 
history or revealed by imaging), type I diabetes, 
severe heart valvar disease, and myocardial infarc-
tion or cerebrovascular accident 6 months prior 
were excluded; (2) patients who were or would 
have been in pregnancy during the study. 
The study was approved by the ethics com-
mittee of Putuo Hospital Affiliated to Shanghai 
University of Traditional Chinese Medicine. All 
patients had been informed in advance and signed 
a consent form. 
Experimental design
This was a single-centre, prospective, ran-
domized and controlled study. The 60 recruited 
patients were equally and randomly assigned to 
the intervention group undergoing catheter-based 
RDN and the control group receiving drug treat-
ment with the random envelope method, there 
were 30 patients in each group. All involved pa-
tients were followed up for 6 months.
RDN intervention
Before the RDN intervention, patients were 
given enteric-coated acetylsalicylic acid (300 mg) or 
clopidogrel (300 mg) by chewing. During the opera-
tion, patients were given heparin (6000–8000 U) by 
intravenous injection. Femoral artery puncture were 
conducted after skin preparation in right fold inguen 
and disinfection; then 7 F vascular sheath was im-
bedded. Renal arteriography was conducted in both 
left and right with a JR4 catheter. Spiral ablation was 
performed with an imbedded 6 F radiofrequency 
ablation catheter (Ablation instrument [39D-72X]: 
Johnson Medical Instrument Co. Ltd.) in temperature 
control mode (8–10 W, 50°C) to both left and right 
renal arteries. There were 4–6 ablation points in the 
left and right renal arteries respectively. The effective 
ablation time for each point was 60 s and the interval 
between two neighbouring points was 0.5 cm. Renal 
arteriography was conducted after operation.
Study assessment
Efficacy endpoint. All patients accepted 
NT-proBNP test, echocardiographic LVEF assess-
ment and NYHA class assessment both before the 
operation and after 6-month follow up. Six-minute 
walk test was also conducted both preoperatively 
and monthly during the following period. Changes 
in these tests were treated as the efficacy endpoint 
in this study. 
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Safety endpoint. All patients accepted the 
office BP measurement both preoperatively and 
monthly during the follow up. Heart rate and GFR 
were also measured both before the operation 
and after 6-month follow up. Changes in these 
measurements were treated as safety points in 
this study. 
Pharmacological therapies
All patients underwent pharmacotherapy 
for HF with a maximal tolerated dose prior to 
denervation, including beta-blockers, angiotensin 
converting enzyme (ACE) inhibitors or endothelin 
receptor antagonist, and spironolactone. No change 
of medications was permitted prior to denervation. 
During the following, patients were given standard 
HF care and the physicians could freely adjust the 
dosage of pharmacotherapy according to patient 
condition, e.g., changes in BP and heart rate.  
Statistical analysis
Statistical analyses were carried out with 
the SPSS 21.0 statistical analysis package (SPSS 
Inc., New York, USA). All measurement data were 
presented as mean ± standard deviation (SD); 
while, the enumeration data were presented as 
a percentage number. The comparison of measure-
ment data was achieved by the student independent 
t-test with a prior checking of dataset normality by 
Shapiro-Wilk test; and for enumeration data, they 
were compared by c2 test or the Fisher exact test. 
Statistical difference was defined as the situation 
where p-value was smaller than 0.05.
Results
Baseline clinical characteristics
Sixty patients (13 females and 47 males) with 
a mean age of 60.2 ± 11.6 years were enrolled in 
this randomized controlled study between January 
2014 and July 2015. Their mean body mass index 
was 26.7 ± 2.7 kg/m2. Among these patients, 65.0% 
were with hypertension, 58.3% were with coronal 
heart disease, 11.7% were with atrial fibrillation, 
and 25% were with type 2 diabetes. All patients 
were diagnosed as chronic HF (NYHA class II 
or III, NT-proBNP level is 791.2 ± 363.7 pg/mL, 
6-minute walk distance is 213.8 ± 65.9 m, and the 
LVEF is 34.9 ± 3.2% during the echocardiogram). 
There was  a mean GFR of 100.6 ± 33.9 mL/ 
/min/1.73 m2, mean office systolic BP was 142.6 ± 
± 22.6 mmHg, mean diastolic BP was 80.8 ± 12.6 
mmHg, and mean heart rate was 69.1 ± 7.3 bpm. 
In addition, 95% of patients were treated with 
ACE inhibitors or angiotensin II receptor blockers, 
78.3% with beta-blockers, 16.7 % with aldosterone 
antagonists, 43.3% with calcium-channel blockers, 
6.7% with digoxin, and 50% with loop diuretics.
Bilateral renal denervation was successfully 
performed in all 30 patients in the RDN group. No 
statistically significant difference was found be-
tween the two groups in age, sex, most comorbidi-
ties, reported duration spent on pharmacotherapy 
for HF, and assessments of effectiveness and safety 
endpoints (Table 1).  
Efficacy endpoint
All patients in both groups were followed up 
for 6 months. Results of the Student independent 
t-test on NT-proBNP indicates that the NT-proBNP 
levels in RDN group (440.1 ± 226.5 pg/mL) were 
significantly lower (p < 0.001, Cohen’s d = 1.14) 
than those in the control group (790.8 ± 287.0 pg/ 
/mL) in the 6th month follow up (Fig. 1).
The effects of RDN on cardiac functions of 
patients with chronic HF can be indicated by the 
results of independent t-tests on echocardiographic 
parameters between the two groups (Table 2). 
It is seen that LVEF significantly increased 
(p = 0.017, Cohen’s d = 0.61) in the RDN group 
(39.1 ± 7.3%) when compared with the control 
group (35.6 ± 3.3%) at the end of the 6-month 
follow up. Further, left ventricular end systolic 
diameters in the RDN group (46.4 ± 4.7 mm) were 
significantly smaller (p < 0.001, Cohen’s d = 0.87) 
than those in the control group (50.2 ± 3.1 mm); 
nevertheless, no statistically significant difference 
was found in left ventricular end diastolic diameter 
and interventricular septal thickness between the 
two groups (p > 0.05).
After 6-month follow up, patients in the RDN 
group showed an improvement of cardiac function, 
with 7 patients showing better results of NYHA 
class assessment (Fig. 2). The 6-minute walk 
distance in the RDN group (301.2 ± 139.5 m) was 
significantly increased (p = 0.01, Cohen’s d = 0.66) 
when compared with the control group (227.2 ± 
± 65.0 m) in the 6th month (Fig. 3). 
Safety endpoint
In the 6th month, the office BP of patients in the 
RDN group (123.3 ± 0.9 / 68.5 ± 7.0 mmHg) sig-
nificantly decreased (p < 0.001, Cohen’s d = 0.91) 
when compared with those in the control 
group (139.8 ± 20.7 / 80.2 ± 11.8 mmHg), as shown 
in Figure 4; nevertheless, no patient reported 
symptoms of hypotension syncope or amaurosis 
during the follow up period. No significant differ-
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ence was found for heart rates (p = 0.062, Cohen’s 
d = 0.49) and GFR (p = 0.209, Cohen’s d = 0.33) 
between the two groups after 6-month follow up, 
even though there was a slight decrease in heart rate 
and an increase in GFR were observed (Figs. 5, 6).
Discussion
This was a prospective randomized and con-
trolled study to explore the effectiveness and safety 
of cathedral-based RDN on patients with chronic 
systolic HF. The improvement of exercise toler-
ance, decrease of NT-proBNP level, and increase of 
LVEF at echocardiography, suggest the feasibility 
and effectiveness of RDN in treatment of chronic 
systolic HF. In addition, no amaurosis and syncope 
in the RDN group, as well as no significant differ-
ence between-group of GFR further indicate the 
safety of RDN treatment. 
Renal denervation has never been proposed 
as an effective way to treat resistant hypertension 
[6, 7], but its effect on this specific disease was 
inconclusive due to disappointing results acquired 
in the SIMPLICITY HTN-3 study, no significant dif-
ference was found in reduced BP between the RDN 
and sham groups [8]. Even though, recent studies 
proposed that RDN might be an effective way for 
the treatment of HF [12], due to its abilities in 
Table 1. Baseline patient characteristics, demographics, background medications, efficacy and safety 
endpoints parameters in renal denervation and control groups.
Renal denervation group  
(n = 30)
Control group   
(n = 30)
P
Age [years] 59.0 (12.1) 61.3 (11.1) 0.446
Sex [male] 25 (83.3%) 22 (73%) 0.347
Body mass index [kg/m2] 26.8 (2.6) 26.7 (2.8) 0.939
Medical history:
Hypertension 21 (70.0%) 18 (60.0%) 0.417
Coronary heart disease 17 (56.7%) 18 (60.0%) 0.793
Atrial fibrillation 4 (13.3%) 3 (10.0%) 0.688
Type 2 diabetes 8 (26.7%) 7 (23.3%) 0.766
Patients receiving drug class:
ACE or ARB 29 (96.7%) 28 (93.3%) 1.000
Beta-blockers 23 (76.7%) 24 (80.0%) 0.754
Aldosterone antagonists 6 (20.0%) 4 (13.3%) 0.488
Calcium-channel blockers 14 (46.7%) 12 (40.0%) 0.602
Digoxin 3 (10%) 1 (3.3%) 0.612
Loop diuretics 14 (46.7%) 16 (53.3%) 0.606
Hemoglobin 119.1 (25.9) 112.3 (24.5) 0.299
Efficacy endpoint:
NT-proBNP [pg/mL] 797.7 (356.1) 784.7 (377.1) 0.892
Six minute walk test [m] 217.5 (69.5) 210.0 (63.0) 0.666
NYHA class:
Class II 17 (56.7%) 16 (53.3%) 0.795
Class III 13 (43.3%) 14 (46.7%) 0.795
Echocardiographic LVEF [%] 35.0 (3.2) 34.8 (3.2) 0.872
Safety endpoint:
GFR [mL/min/1.73 m2] 104.8 (35.9) 96.4 (31.8) 0.337
Symbolic BP [mmHg] 142.0 (24.8) 143.2 (20.7) 0.844
Diastolic BP [mmHg] 79.8 (12.6) 81.7 (12.9) 0.579
Heart rate [bpm] 68.7 (7.9) 69.4 (6.9) 0.728
Data are mean (standard deviation) or number (%). ACE — angiotensin-converting enzyme inhibitor; ARB — angiotensin II receptor blocker; 
BP — blood pressure; GFR — glomerular filtration rate; LVEF — left ventricular ejection fraction; NT-proBNP — N-terminal pro-B-type natriu-
retic peptide; NYHA — New York Heart Association
www.cardiologyjournal.org 507
Jun-Qing Gao et al., RDN with chronic systolic heart failure
suppressing activities of the sympathetic nervous 
system and renin–angiotensin–aldosterone system 
(RASS) by blocking the renal sympathetic nerve. 
It should be noted that excessive activation of the 
sympathetic nerves and the over expression of 
RASS are believed to be major contributors to the 
cause and development of HF [13]. Actually, exces-
sive activation of the renal sympathetic nerves can 
lead to renal vasoconstriction and increase renin 
secretion as well as proximal tubular sodium re-
absorption [14]. This kind of chronic stimulation 
caused by excessive activation of the sympathetic 
nerves can lead to volume overloading, myocardial 
remodeling and cardiovascular function deteriora-
tion [15]. 
Accumulating animal evidence suggests that 
RDN is able to bring hemodynamic changes and im-
prove cardiac functions. For example, RDN showed 
an effective inhibition on RASS in a porcine model 
of pacing-induced HF [11]. After pacing, the RDN 
group has shown a significantly higher LVEF at 
echocardiography and a significantly lower plasma 
concentration of renin, relative to the control 
group. In contrast, although a significant elevated 
plasma concentration of aldosterone was reported 
in the control group, no significant change in the 
aldosterone level was observed in the RDN group. 
Similar results have been found in a rat model of 
Figure 1. Mean N-terminal pro B-type natriuretic peptide 
(NT-proBNP) level at 6 months after renal denervation 
(RDN) in the RDN and control groups. A significant 
decrease in the RDN group was observed. Error bars 
indicate standard errors.
Table 2. Changes in echocardiographic parameters before and 6 months after randomization in the  
renal denervation (RDN) and control groups.
Parameter Baseline 6 months
RDN Control P RDN Control P
LVEF [%] 35.0 ± 3.2 34.8 ± 3.2 0.872 39.1 ± 7.3 35.6 ± 3.3 0.017
LVESD [mm] 50.3 ± 3.3 51.4 ± 2.4 0.156 46.4 ± 4.7 50.2 ± 3.1 < 0.001
LVEDD [mm] 63.3 ± 4.5 63.6 ± 4.7 0.082 60.0 ± 6.7 62.5 ± 4.5 0.106
IVST [mm] 10.3 ± 1.3 10.2 ± 1.3 0.848 9.5 ± 0.9 9.6 ± 0.9 0.575
Data are mean ± standard deviation. LVEF — left ventricular ejection fraction; LVESD — left ventricular end systolic diameter; LVEDD — left 
ventricular end diastolic diameter; IVST — interventricular septal thickness
Figure 2. New York Heart Association (NYHA) class as-
sessment in the renal denervation (RDN) and control 
groups at baseline and at 6 months after RDN. Black 
bars indicate NYHA class III. Blue bars indicate NYHA 
class II. Gray bars indicate NYHA class I. 
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isoproterenol induced chronic HF. It was reported 
that RDN down-regulated the protein expression 
of angiotensin II in myocardial tissue of rats left 
atrial, and thereby improved the cardiac function, 
shown by an increased LVEF [10]. Moreover, RDN 
was reported to be able to improve the cardiac 
function and inhibit myocardial remodeling in rats 
with post-myocardial infarction [9]. Further animal 
study has suggested that denervation intervention 
can ameliorate progression of left ventricular hyper-
trophy in spontaneously hypertensive rats, probably 
due to the reduction of BP and lower expression of 
inflammatory factors (e.g., TLR4, NF-kB, TNF-a, 
and IL-6) in myocardial tissue [16].
Figure 3. Change in 6 minute walk test before and after renal denervation (RDN) for RDN and control groups. A 6 min-
ute walk test was measured at baseline and over a 6 month follow-up. A significant improvement in 6 minute walking 
distance was observed in the RDN group over 6 months. Error bars indicate standard errors. 
Figure 4. Paired changes of systolic blood pressure (SBP) and diastolic blood pressure (DBP) before and after renal 
denervation (RDN) for RDN and control groups. Blood pressure was measured at baseline and over a 6 month follow-
up. Significant reductions in blood pressure were observed in the RDN group over 6 months. Error bars indicate 
standard errors.
0
40
20
80
60
100
120
140
160
180
B
lo
o
d
 p
re
s
s
u
re
 [
m
m
H
g
]
SBP for RDN group SBP for control group
DBP for RDN group DBP for control group
Baseline 1 month 2 months 3 months 4 months 5 months 6 months
0
100
50
200
150
250
300
350
400
450
500
E
x
c
e
ri
s
e
 d
is
ta
n
c
e
 [
m
]
RDN group
Control group
Baseline 1 month 2 months 3 months 4 months 5 months 6 months
www.cardiologyjournal.org 509
Jun-Qing Gao et al., RDN with chronic systolic heart failure
Figure 5. Mean heart rate at 6 months after renal dener-
vation (RDN) in the RDN and control groups. No signifi-
cant between-group differences were observed. Error 
bars indicate standard errors. 
Figure 6. Mean glomerular filtration rate (GFR) at 
6 months after renal denervation (RDN) in the RDN and 
control groups. No significant between-group differenc-
es were observed. Error bars indicate standard errors. 
Though the positive results have been well 
confirmed in animal studies, the effects of RDN 
on patients with HF are still not well documented, 
and some indirect evidence were reported in stud-
ies on treatment of resistant hypertension. For 
example, a study including 72 patients reported 
that RDN could ameliorate the cardiac function, 
indicated by an improvement in left ventricular 
mass index, left ventricular mass/body surface 
area ratio, left ventricular wall stress, as well as 
LVEF values [17]. Another study also reported 
that the resistant hypertension patients were also 
accompanied with left ventricular hypertrophy and 
diastolic dysfunction [18]. These results together 
suggest that RDN would be promising treatment 
for HF, especially for that accompanied with hy-
pertension. Actually, the REACH-Pilot study has 
once investigated the effects of RDN on patients 
with HF and reported that RDN could improve 
patient exercise tolerances [12]. Nevertheless, 
this study was limited by its small sample size and 
its single-group non-blinded and non-randomized 
nature [19]. Here, more patients were recruited 
and a randomized controlled trial was performed for 
more convincing results. Obtained results verfied 
the values of RDN in improving the cardiac function 
and treating patients with HF. 
The RDN group in this study had shown 
a reduction in BP of approximately 20 mmHg over 
6-month follow up. However, such changes in BP 
did not accompany any symptoms of hypotension, 
indicating that this intervention did not lead to 
symphonic problems in patients with chronic sys-
tolic HF. Furthermore, patients receiving RDN 
showed no changes in GFR and heart rate before 
and after the procedures. The reduction of BP has 
been suggested to potentially dampen the impair-
ment of renal function, as a decreased BP may 
help reduce the sympathetic outflow to the kidney 
[6]. In this study, the hemodynamic changes and 
normal renal function show no adverse effects on 
the kidneys of patients with chronic systolic BP, 
suggesting the safety of RDN.
Limitations of the study
Several limitations need to be noted in this 
study. First, the number of patients with systolic 
HF for RDN procedure was not large, thereby 
limiting statistical power. However, the improve-
ment of cardiac function in the present popula-
tion is in line with that of previous studies in 
hypertension with a large sample size. Second, 
non-blinded or sham-procedure group was not 
provided. The results, therefore, may contain 
bias. A randomized controlled trial with a sham 
group should be done to further investigate the 
effectiveness of RDN in HF. Third, whether RDN 
treatment in chronic systolic HF could improve 
a patients’ diuretic need or resistance warrants 
further investigation. 
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Conclusions
Catheter-based RDN with radiofrequency abla-
tion has shown to be very promising in improving 
cardiac function and exercise tolerance for patients 
with chronic systolic HF, in the present single-
center, randomized, controlled trial. No adverse 
effects on the kidneys of patients should also be 
noted. Thus, this innovative technique can be an 
effective and safe new therapy for chronic systolic 
HF, even though more long-term experimental and 
clinical evidence should be provided in the future 
studies.
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